Pernix Therapeutics Announces Positive Phase IV Results of Silenor® vs. Zolpidem Head-to-Head Arousability Study
June 16, 2016 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
Data demonstrated that Pernix Therapeutics’ Silenor® 6 mg was superior to zolpidem 10 mg on all measures evaluated. Study results presented at SLEEP 2016 international meeting MORRISTOWN, N.J.,...
Pernix Therapeutics Holdings, Inc. Announces Positive Interim Results From a Phase IV Study to Assess and Compare the Effects of Silenor 6 mg and zolpidem 10 mg on Balance, Cognitive Performance, and Arousability
November 12, 2015 11:15 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced positive interim results from a Phase IV...